



Multi-input stochastic prediction of insulin sensitivity for 
tight glycaemic control using insulin sensitivity and blood 
glucose data 
 
Shaun Davidson1, Chris Pretty1, Vincent Uyttendaele2, Jennifer Knopp1, Thomas Desaive2, J. 
Geoffrey Chase1 
 
1Department of Mechanical Engineering, University of Canterbury, Christchurch, New 
Zealand 
2GIGA-Cardiovascular Sciences, University of Liège, Liège, Belgium 
 
Phone: +64 3-369 0065 
Fax: +64 3-369 0065 
E-mail: shaun.davidson@canterbury.ac.nz 





Background: Glycaemic control in the intensive care unit is dependent on effective prediction 
of patient insulin sensitivity (SI). The stochastic targeted (STAR) controller uses a 2D 
stochastic model for prediction, with current SI as an input and future SI as an output.  
Methods: This paper develops an extension of the STAR 2D stochastic model into 3D by 
adding blood glucose (G) as an input. The performance of the 2D and 3D stochastic models is 
compared over a retrospective cohort of 65,269 data points across 1,525 patients.  
Results: Under five-fold cross-validation, the 3D model was found to better match the 
expected potion of data points within, above and below various credible intervals, suggesting 
it provided a better representation of the underlying probability field. The 3D model was also 
found to provide an 18.1% narrower 90% credible interval on average, and a narrower 90% 
credible interval in 96.4% of cases, suggesting it provided more accurate predictions of future 
SI. Additionally, the 3D stochastic model was found to avoid the undesirable tendency of the 
2D model to overestimate SI for patients with high G, and underestimate SI for patients with 
low G.  
Conclusions: Overall, the 3D stochastic model is shown to provide clear potential benefits 
over the 2D model for minimal clinical cost or effort, though further exploration into whether 
these improvements in SI prediction translate into improved clinical outcomes is required. 
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Stress-induced hyperglycaemia is frequently observed in intensive care unit (ICU) patients [1-
3]. Both this hyperglycaemia [1, 2, 4] and general glycaemic variability [5, 6] have been 
associated with increased morbidity and mortality. As such, effective glycaemic control that is 
capable of regulating blood glucose (G) levels to within a safe and relatively narrow band by 
modulating insulin and nutrition infusion rates may help alleviate these negative effects [7-12], 
improving patient outcomes and reducing cost of care. 
However, patient insulin sensitivity (SI), which governs glycaemic response, undergoes 
complex and highly variable stress-induced changes [13, 14]. Thus, safe, effective control of 
patient G is reliant on effective and accurate prediction of future patient SI [15-17]. Failure to 
effectively account for variability in future SI can lead to an increased risk of hypoglycaemia, 
as in [18-25], where 17–29 % of patients had at least one blood glucose reading of less than 
2.2 mmol/L. Hypoglycaemia is associated with increased mortality [26-28], and often occurs 
due to large, difficult to predict changes in patient SI over short periods [14, 29, 30]. These 
large changes in patient SI are particularly frequent in the first 48 hours post ICU admission 
[31], where there is a concordant, high rate of hypoglycaemic events and a strong association  
with mortality [27]. 
The stochastic targeted (STAR) protocol [15, 16] combines a clinically validated model of the 
insulin-glucose system [32, 33] with a stochastic model for predicting future variability in SI 
[34, 35]. STAR titrates patient and condition specific insulin and nutrition interventions, 
designed to minimise hyperglycaemia, while maintaining a low risk of a mild hypoglycaemia 
(no more than 5% risk of G less than 4.4 mmol/L [15-17] ). Thus, STAR is designed to provide 




patient variability. Since 2011, STAR has been the standard of care in the ICUs of both the 
Christchurch Hospital, New Zealand, and Kálmán Pándy Hospital, Hungary, demonstrating 
safe and effective control to the targeted range in these two cohorts [36]. 
The current stochastic model prediction of future SI involves a 2D kernel combining current 
insulin sensitivity (SIt) and future insulin sensitivity (SIt+1) over a cohort of representative, 
retrospective data [34]. With the increased availability of retrospective information since 
STAR’s inception in 2011, there has been interest in adding additional information and 
dimensions to this stochastic model. Previous studies have explored using further historic SI 
values (e.g. SIt-1) or historic variability in SI [37, 38]. This study instead explores the effects of 
the addition of a different data type, current blood glucose (Gt), which is consistently measured 
in the ICU and is used in the ICING model as well as by the STAR protocol to titrate treatment, 
but not in the kernel-based model predictor. The overall aim of this paper is to develop a 





2 Materials and Methods 
2.1 The ICING Model 
STAR employs the clinically validated ICING metabolic model [35, 39-41] to account for 
dynamic SI as encountered in critical care. This model is defined: 
?̇? = −𝑝𝐺 ∙ 𝐺 − 𝑆𝐼 ∙ 𝐺 ∙
𝑄
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?̇? = 𝑛𝐼 ∙ (𝐼 − 𝑄) − 𝑛𝐶 ∙
𝑄
1 + 𝛼𝐺 ∙ 𝑄
 (3) 
?̇?1 = −𝑑1 ∙ 𝑃1 + 𝑃(𝑡) (4) 
?̇?2 = −min(𝑑2 ∙ 𝑃2, 𝑃max) + 𝑑1 ∙ 𝑃1 (5) 
where G (mmol/L) is the blood glucose concentration, I (mU/L) is the blood insulin 
concentration and Q (mU/L) is the interstitial insulin concentration. P1 and P2 represent the 
total stomach and gut glucose, respectively, and serve to model the rate at which enteral feed 
P(t) (mmol/min) enters the blood. Clinically measured or recorded model inputs are enteral 
feed rate P(t), parenteral feed rate PN(t), blood glucose G(t), and exogenous insulin infusion 
rate uex(t). Pancreatic insulin secretion, uen(G), is modelled as a linear piecewise function of 
G(t) [41]. The remaining parameters are fixed, population standard values, and are provided in 
Table 1. Integral based fitting [42, 43] is used to fit a single parameter: a constant SI over a 
period of 60 minutes. To fit this SI, a linear profile for G(t) is assumed, as well as steady state 
initial conditions if no previous I or Q has been calculated for the patient (i.e. for the initial 
measurement for each patient). Further details on the ICING model can be found in [43, 44]. 




Parameter Value Description 
pG 0.006 min
-1 Endogenous glucose clearance 
αG 1/65 l/mU Saturation of insulin-mediated glucose uptake 
VG 13.3 L Glucose distribution volume 
EGP 1.16 mmol/min Endogenous glucose production (hepatic) 
CNS 0.3 mmol/min Glucose uptake by central nervous system 
d1 -ln(0.5)/20 min
-1 Gastric emptying of stomach to gut 
d2 -ln(0.5)/100 min
-1 Glucose absorption for gut to bloodstream 
Pmax 6.11 mmol/min Maximum glucose absorption rate from gut 
xL 0.67 Fractional first pass hepatic insulin clearance from portal vein 
nL 0.1578 min
-1 General hepatic insulin clearance 
αI 1.7 x 10
-3 L/mU Saturation of hepatic insulin clearance 
nK 0.0542 min
-1 Kidney clearance of insulin 
nC 0.0075 min
-1 Cellular degradation of internalised insulin 
nI 0.0075 min
-1 Insulin diffusion between plasma and interstitium 
k1 14.9 mU·L/mmol/min Insulin secretion model parameter 
k2 -49.9 mU/min Insulin secretion model parameter 
umin 16.7 mU/min Minimal insulin secretion 
umax 266.7 mU/min Maximal insulin secretion 
VI 4.0 L Insulin distribution volume 
 
The SI parameter in the ICING model has been shown to broadly capture patient metabolic 
response to insulin and nutrition inputs, and therefore be a key factor in control efficacy [29]. 
Thus, SI provided by the ICING model is both physiologically relevant and important to the 
safety and efficacy of glycaemic control. 
2.2 Clinical Data Set 
2.2.1 Cohort 
The data employed in this study is drawn from three cohorts also employed in [36], largely 
gathered using the STAR tablet interface:  
1. Patients from the Christchurch Hospital ICU, Christchurch, New Zealand, treated using 




2. Patients from the Kálmán Pándy Hospital ICU, Gyula, Hungary, treated using the 
STAR protocol between December 2011 and May 2015. 
3. Patients from the Christchurch Hospital ICU, Christchurch, NZ, treated using the 
Specialized Relative Insulin and Nutrition Tables (SPRINT) protocol [8, 10], the 
predecessor of STAR, between July 2005 and May 2007.  
And one additional cohort: 
4. Patients from the Christchurch Hospital ICU, Christchurch, New Zealand, treated using 
the STAR protocol and a modified, clinically driven nutrition protocol between June 
2015 and November 2017. 
Unlike in [36], where the goal was the assessment of the effectiveness of the STAR controller, 
and patients who were treated outside of guidelines or for a short period of time were excluded, 
the focus here is to capture glucose-insulin dynamics, which can be captured irrespective of 
compliance to the protocol. Overall, this data set encompassed 1,525 patients. For information 
on the demographics of cohorts 1 – 3, see [36]. 
2.2.2 Ethics, consent and permissions 
Approval for a retrospective audit, analysis and publication of Christchurch patient data was 
provided by the Upper South Regional Ethics Committee, New Zealand. According to local 
ethical codes in Hungary, publication of anonymized, retrospective data, as here, is considered 
a clinical data audit.  
2.2.3 Data Processing 
The patient data set included enteral feed rate P(t), parenteral feed rate PN(t), exogenous insulin 




measurement was performed using an Arkray Super-Glucocard™ II glucometer (Arkray, 
Minnesota, USA) (2011–2012) or a Roche Accu-Chek Inform II (F. Hoffmann-La Roche Ltd, 
Basel, Switzerland) (2012–2017) and blood taken directly from an arterial line. At each glucose 
assay point, SIt was derived by solving for a constant SI over the 60-minute period directly 
prior to the assay and SIt+1 by solving for a constant SI over the 60-minute period directly after 
the assay [42, 45]. As such, only patient data points with both a prior and future Gt assay 
available were usable in the model, giving a total of 65,269 usable patient data points. 
As shown in Fig. 1, the overall distribution of the datasets SIt, Gt and SIt+1 all appear to be log-
normal, and SI and G, for physiological and physical reasons, should not be negative, 
corresponding to the logarithmic domain. As several kernel rules employed in this paper (e.g. 
Silverman’s Rule [46]) are defined under assumptions of normally distributed data, all three 
variables were log transformed prior to generation of the 3D kernel field. This transformation 
shifts the log-normal data into an apparently normal distribution, as shown in Fig. 1, though 
the data set is too large for normality tests to be performed effectively [47].  
As demonstrated by the effectiveness of the current 2D stochastic model [34], there are strong 
correlations between the data even prior to this transformation. Stochastic prediction of future 
SI using current SI is supported by a strong autocorrelation, with values of R = 0.87, 0.85, and 
0.80 at lags of t = 1, 2, and 3 hours respectively, where 3 hours is the maximum prediction 
interval used in the STAR protocol [15, 16]. These values were calculated by using non-












2.3 3D Stochastic Model 
This model employs a multivariate Gaussian normal kernel, which will behave in a log-normal 
fashion due to the logarithmic transformations on the input data. For n variables, the Gaussian 









Where C is the n x n covariance matrix, y is a query point in n-dimensional space, and x is the 
centre point of the kernel. 
2.3.1 Ortho-Normalisation 
Ortho-normalisation involves transformation of the data so that it is centred at 0, has a standard 
deviation and variance of 1 in every direction, and no correlation exists between the 
transformed variables. These properties have a number of positive effects on kernel calculation, 
as will be shown.  






Perform the Cholesky decomposition on C, the n x n covariance matrix between the variables 
in X, and use the resulting matrix R to define the n x n transformation matrix A: 
𝐂 = 𝐑 × 𝐑T (8a) 
𝐀 = (𝐑T)−1 (8b) 




?̂? = 𝐗 − 𝐞𝑘 × ?̅? (9) 
Where ek is a k x 1 vector of ones and x̄ is a 1 x n vector containing the mean value of each of 
the n variables. The zero-meaned variables can now be transformed into ortho-normalised 
space: 
?̃? = 𝐀 × ?̂? (10) 
Given the aforementioned properties of ortho-normalised space, the ortho-normalised 
covariance matrix C̃ is the identity matrix. As such, the iso-probability shells of the Gaussian 
normal kernels will take the form of n-dimensional hyperspheres in this ortho-normalised 
space, while behaving as non-axis aligned n-dimensional hyperellipsoids in solution space. An 
example of this in 2D is shown in Fig. 2. 
















?̃? = 𝐀 × (𝐲 − ?̅?) (12a) 






Fig. 2: The rectangular grid in solution space (top) becomes a parallelogram in ortho-
normalised space (bottom), causing the circular kernels in ortho-normalised space (bottom) to 
appear as non-axis aligned ellipses in solution space (top). Note the contours are log-density 
contours, selected to highlight the boundaries of individual kernels, and that the outlying 




2.3.2 Kernel Specific Variance, σ̃ 
For each ortho-normalised kernel data point, xj̃, in the matrix X̃, there is an associated kernel 
variance, σj̃. Note that, as the iso-probability shells of the ortho-normalised kernels are 
spherical, this σ̃j applies in all directions for a given kernel data point. Combining Silverman’s 
rule of thumb with a relative local density factor as in [34] yields Eq. 13 for σ̃j in the 3D case 
(full derivation in Appendix A): 











for a given ortho-normalised kernel data point xj̃. Here mj is the number of points in X̃ within 
a radius 𝑘−
1
7 from the kernel data point xj̃ and RZ is the radius from the ortho-normalised centre 
point of 0 that contains Z∙k kernel data points for some Z ≤ 1. Z allows for the exclusion of 
outlying data points that can dramatically alter the global data density calculation. 
2.3.3 Sampling Probability Density Functions for Patient Data Points 
At a query point, y, the probability density, f(y), is the sum of all k kernel data point probability 




































?̃?𝑗 = 𝐀 × (𝐱𝑗 − ?̅?) (15b) 
Here, there are 2 pieces of input patient data, y1 = SIt and y2 = Gt, and 1 output for which a 
probability density function (PDF) is sought, y3 = SIt+1. Determining the conditional 1D PDF, 
f1, for a given patient data point y1:2 involves sampling across the range of potential values for 








  (16) 
where f(Y) refers specifically to Eq. 14, and Y is the line consisting of points y across the full 
range of possible y3 values at y1:2: 
𝑆𝐼𝑡+1,min ≤ 𝑦3 ≤ 𝑆𝐼𝑡+1,max (17) 
The first 2 transformed components of the query point ỹ1:2 and kernel centre point xj̃,1:2 are 
independent of changes in y3 due to the transformation matrix A being upper triangular. This 






































𝑆𝐼𝑡+1,min ≤ 𝑦3 ≤ 𝑆𝐼𝑡+1,max (19) 
This modification is an application of conditional probability rules, which can be used here as 
the transformed variables in ỹ and x ̃ are independent and uncorrelated (unlike their non-
transformed counterparts, another advantage of ortho-normalisation). The first term in Eq. 19 




only needs to be calculated once per kernel centre point xj̃. The second term, which includes 
ỹ3, is the only part that varies, for a given kernel centre point, along the line Y. 
Further computational efficiency can be gained when calculating f1(Y) by restricting 
calculation of constituent kernel probability density functions to cases where, for a given 
sample point, y on the line Y: 
‖?̃? − ?̃?𝑗‖2 < 5?̃?𝑗 (20) 
Given the spherical shape of kernel iso-probability shells in 3D ortho-normalised space ensures 
σ̃j is identical in all directions, this restriction can easily be set geometrically, without requiring 
the calculation of a norm at every point y, as explained in Appendix B. The selected radius can 
be varied based on accuracy and computational load requirements. A radius of 5σ̃j contains 
99.998% of the probability density function in 3D, compared to 99.887% at 4σ̃j and 97.071% 
at 3σ̃j. 1D PDFs were found using pre-calculated values for the transformation matrix A and σ̃j 
values, neither of which change throughout sample space, and at a resolution of 300 points 
along the PDF. Under these conditions, the alteration in Eq. 20 decreased computational time 
from 28.38 s per PDF, using conditional probabilities as in Eq. 18, to 0.24s, using both Eqs. 18 
and 20, on average, a factor of over 118 times.  
STAR currently uses a 400 point table of SIt values with pre-calculated 5% and 95% SIt+1 
credible interval bounds, and interpolates to find the credible interval bounds for a given patient 
SIt. However, this approach is considerably less desirable for a 3D kernel field with a 2D input. 
First, for a 2D input there is a need to store a 400 by 400 table of 160,000 pre-calculated 5% 
and 95% bounds to achieve the same resolution as the 1D table. Second, interpolation error 
increases in higher dimensions due to interactions between errors in individual input variables. 




normal kernels, making interpolation generally less desirable. The improvement in 
computational efficiency provided by Eq. 20 potentially allows the ‘live’ calculation of credible 
interval boundaries, the equivalent of an infinite grid resolution, addressing the various 
concerns listed above. In addition, this approach provides the entire PDF rather than solely the 
5% and 95% bounds. Finally, ‘live’ calculation of credible interval boundaries raises the 
possibility of real-time updating of the stochastic model using weighted kernels for the current 
patient’s previous data points, increasing model personalisation. 
2.4 2D Stochastic Model 
The existing stochastic model employs a 2D multivariate Gaussian normal kernel with SIt used 
as an input for prediction of SIt+1. The primary differences between this model and the 3D 
model, other than the shift between 3D and 2D, are: 
 The data are not log transformed. Thus, the kernels have a normal, rather than log-
normal, form. As this difference allows kernel mass to exist below SI = 0, any kernel 
mass below 0 is removed, and each kernel then normalised to restore that kernel’s mass 
to 1.0. 
 Covariance terms between SIt and SIt+1 are not considered, thus the major and minor 
axes of the kernel iso-density contours are aligned with the axes SIt and SIt+1. 
Accordingly, the data does not undergo an ortho-normalisation, and for each kernel σ 
is calculated separately for SIt and SIt+1. 












































Here, Di is the global standard deviation for the ith variable. Full details on this stochastic model 
can be found in [34, 35]. 
2.5 Validation and Assessment 
Several analyses were performed to validate the model was functioning correctly and evaluate 
the resultant performance changes from the existing 2D model. Note both models were built 
across the entire, current cohort of patient data for equivalence. 
2.5.1 Five-Fold Cross-Validation 
To mitigate issues with developing and then validating the data over the same data set, across 
which, by definition, each credible interval would contain the correct amount of data, five-fold 
cross-validation was used [48]. Cross-validation involved breaking the data into 5 
approximately equally sized sets, and testing each data set on a model built from the other 4 
data sets. This process ensures that the model is built and then assessed on separate datasets 
each time. 
Slight variation in data set sizes arose due to the decision to treat each patient’s set of data 




on a model developed without any data from that same patient. This analysis allows evaluation 
of the accuracy of the credible intervals generated by the model, and thus whether an 
appropriate kernel width, σ ̃, has been selected. Kernel width was modified by altering the term 
Z, changing the normalisation component of the relative data density term in Eq. 13. The final 
values selected were Z = 0.97 for the 2D model and Z = 0.999 for the 3D model, based on 
cross-validation results with the goal of providing as accurate a 90% credible interval as 
possible. 
2.5.2 Comparison of Credible interval Bounds 
This analysis involves a comparison of the credible interval boundaries and widths across all 
patient data, using cross validation to avoid building and evaluating a model on the same data 
set. It intends to provide a general indication and summary statistics of the confidence with 
which estimation of SIt+1 can be achieved, using SIt and Gt. Particular focus is given to the 90% 
credible interval boundary, as the 5th and 95th percentiles are used by STAR to titrate treatment 
[15, 16]. This analysis was accompanied by a visual representation of the credible interval 
boundary surfaces between the 3D and 2D models, built using the entire data set, allowing 
visual comparison of trends in these boundary surfaces across the two models. 
2.5.3 Distribution of Data Points Outside Bounds 
An analysis of the distribution of data points that sat above or below the 90% credible interval, 
the interval boundary used clinically by STAR was carried out as this cohort of patients are 
those for whom the model had over- or under- estimated SI. The aim is to examine the clinical 





3.1 Five-Fold Cross-Validation 
The percentage of SIt+1 data points within, above, and below forward credible interval bounds 
for the 2D and 3D stochastic models using the five sets of cross-validated data are shown in 
Table 2. The percentage of SIt+1 data points within, above, and below bounds for the 3D model 
correspond more closely to the expected percentages for all intervals assessed, except for the 
percentage of data points within the 90% credible interval (90.28% for the 3D kernel and 
90.24% for the 2D kernel). Across the bounds tested, the 3D model provides percentages of 
data points within, above and below bounds that are 2.6 times closer to the expected 
percentages, on average, than the 2D model. Additionally, at the 90% and 95% credible interval 
for the 2D model there is a notably greater portion of points below than above the credible 
interval bounds, while the 3D model maintains reasonably even portions of both. Further, the 
2D model fails to provide 95% of points within the 95% credible interval bounds, while the 3D 
model continues to show a good match to the data. Thus, the 3D model is more reflective of 
the underlying data than the 2D model, and may be better suited to predict SIt+1. 
Table 2: Cross-Validation Results, 2D and 3D stochastic models. Values reflect the 
percentage of SIt+1 points that fell below, within, or above credible interval bounds. 
Credible Interval 
2D Stochastic 3D Stochastic 
Below Within Above Below Within Above 
95% 3.77% 94.06% 2.16% 2.50% 95.06% 2.43% 
90% 5.45% 90.24% 4.29% 4.92% 90.28% 4.80% 
75% 11.12% 77.96% 10.91% 11.93% 76.28% 11.78% 





3.2 Credible Interval Bounds 
Credible interval summary statistics for SIt+1 using the 2D and 3D models are presented in 
Table 3. These statistics were generated by calculating credible intervals for each patient data 
point using the previously defined cross-validation model that excluded that patient, and then 
taking the average across all patient data points. From Table 3, the 3D 90% credible interval is 
18.12% narrower on average, with a 6.37% lower 95% boundary and a 14.38% higher 5% 
boundary. Across the full set of data points, the 3D model provides a narrower 90% credible 
interval in 96.15% of cases, and is narrower by 20.95% on average in these cases. The 3D 
model provides a wider credible interval in 3.85% of cases, where it is wider by an average 
amount of 21.21%. Where the 3D model is wider, the mean Gt is 6.02 mmol/L, less than the 
overall average of 6.74 mmol/L, and the mean SIt is 8.75 x 10-4 L/mU/min, over double the 
overall average of 4.24 x 10-4 L/mU/min. Thus, the 3D model is more conservative where risk 
is higher, and narrower where stability in SI allows improved prediction. 
Table 3: Credible interval Summary Statistics. These figures are averages of credible 
intervals generated using a five-fold cross-validation model for each patient data point. 
Model 2D Stochastic 3D Stochastic 
Expected Value 4.24 x 10-4 L/mU/min 4.24 x 10-4 L/mU/min 
5% Boundary 2.26 x 10-4 L/mU/min 2.59 x 10-4 L/mU/min 
95% Boundary 6.25 x 10-4 L/mU/min 5.85 x 10-4 L/mU/min 
90% Interval Width 3.99 x 10-4 L/mU/min 3.27 x 10-4 L/mU/min 
 
Figures 3 and 4 show the 5% and 95% boundary surfaces for the 2D and 3D stochastic models. 
Overlaid upon these figures is the density of clinical data, providing emphasis on which regions 





Fig. 3: The 5% bound for SIt+1 (higher is generally better) for the 2D and 3D stochastic 
models, with data density overlaid 
 
Fig. 4: The 95% bound for SIt+1 (lower is generally better) for the 2D and 3D stochastic 




Of note in Figures 3 and 4 is the tendency for the 3D kernel surface to be higher for lower 
values of Gt, and lower for high values of Gt, showing a clear dependence missed by the 2D 
model. Figure 5 shows the 90% interval width for the 2D and 3D stochastic models. Here it is 
clear that the 3D model produces a narrower credible interval in the majority of cases, 
especially at common clinical values. 
 
Fig. 5: The 90% credible interval width for SIt+1 (narrower is better) for the 2D and 3D 
stochastic models, with data density overlaid 
3.3 Data Points Outside Bounds 
Fig 6. shows histograms of the distribution of Gt, SIt and SIt+1 data point sets within, above, and 
below the 90% cross-validated credible interval for the 2D and 3D models. Of interest is the 
bimodal distribution in the ‘below bounds’ data set from the 2D model for SIt and SIt+1. Also 
of note is the tendency of the 2D model to overestimate SI of patients with high Gt, and 





Fig. 6: Histograms showing the data distribution of points within, above and below the 90% 






The cross-validation results in Table 2 show that the 3D stochastic model provides a better 
representation of the underlying data distribution than the 2D stochastic model, resulting in 
improved prediction of SIt+1. On average, the 3D model provides percentages of predicted SIt+1 
points within, above and below credible interval bounds that are 2.6 times closer to their 
expected percentages than the 2D model. Further, the difference between the expected and 
observed percentage of points within bounds varies less for the 3D model (0.06% to 2.02%) 
than for the 2D model (-0.94% to 4.60%), suggested the log transformation of the data and 
addition of Gt as an axis have resulted in a more representative kernel field. Finally, the 3D 
model maintains relatively even portions of points above and below the credible interval 
bounds, while for the 90% and 95% credible interval, the 2D model provides notably more 
points below than above the credible interval bounds. This result is likely due to the removal 
of kernel mass where SI < 0 for the 2D model, which shifts the centres of these kernels upwards 
and results in systematic overestimation of low values of SIt+1. 
These results are consistent across the repeated developing of the model on 80% of the data 
and evaluating it on the remaining, separate 20% of the data during cross-validation. This 
behaviour suggests that model performance is not a function of data selection, and thus the 
model and kernel choices are valid for the population. Further, the underlying data was 
gathered across multiple glycaemic control protocols, and multiple ICUs in different countries 
with different standards of clinical practice. Thus, the underlying data set is heterogenous, and 
the model and results would be expected to generalise well. 
The results in Table 3 show that the 3D stochastic model is able to provide more accurate 




treatments. The 3D model provides an 18.12% narrower 90% credible interval than the 2D 
model, on average, and a narrower credible interval in 96.15% of cases. This suggests the 2D 
model can be unnecessarily over-conservative in insulin dosing. As this analysis uses the cross 
validated data, with 90.24% of points within the credible interval for the 2D model and 90.28% 
of points within the credible interval for the 3D model, this improvement in performance is 
unlikely to be the result of overfitting. While this result is not entirely unsurprising, given the 
3D model incorporates additional information unavailable to the 2D model, these results 
support that this additional information has been well selected and correctly implemented. 
During the 3.85% of the time the credible interval is wider for the 3D model than the 2D model, 
Gt is lower than average (6.02 mmol/L vs 6.74 mmol/L) and SIt is over double the average 
(8.75 x 10-4 L/mU/min vs 4.24 x 10-4 L/mU/min). This result suggests the 3D model is more 
conservative than the existing model for patients with very high SIt and lower than average Gt, 
desirable to avoid hypoglycaemia. As such, use of more conservative credible intervals for this 
small subset of patients may well be beneficial and provide improved safety. 
The credible interval surfaces in Figs. 3 – 5 suggest a general upward trend at lower levels of 
Gt for the prediction of SIt+1 using the 3D model, a trend which does not, by definition, exist 
for the 2D model. It is possible that this trend is representative of underestimation of SIt+1 
leading to mild over-administration of insulin and a reduction in Gt. Thus, the 3D model serves 
to correct for over- or under- estimation of SIt+1 based on patient response.  
The histograms in Fig. 6 provide a closer look at the patients that fall outside the credible 
interval boundaries for each model, compared to those that lie within the credible interval 
boundaries. The histograms of patient SIt show that there is a bimodal peak to the left of overall 




3D stochastic model. This bimodal peak is likely due to the aforementioned removal of kernel 
mass where SI < 0 in the 2D model, leading to systematic overestimation of low values of SIt+1, 
a problem that is avoided by the log transformation of data in the 3D model, which in turn 
improves model shape and accuracy. 
The histograms in Fig. 6 of patient Gt show that the 2D model, which is blind to Gt, tends to 
overestimate SIt+1 for patients with high Gt, increasing the risk of hyperglycaemia by 
anticipating these patients will be more responsive to insulin than they will actually be. 
Similarly, the 2D model tends to underestimate SIt+1 for patients with low Gt, increasing the 
risk of hypoglycaemia by anticipating these patients will be less responsive to insulin than they 
will actually be. The 3D model, which incorporates Gt, entirely removes these tendencies, 
which has the potential to have significant clinical benefits, as avoiding these hyper- and hypo- 
glycaemic cases is one of the overall goals of glycaemic control, where STAR already has 
excellent safety results [36]. Finally, the histograms of patient SIt+1 show that patients with 
higher than average SIt+1 are more likely to be underestimated, and patients with lower than 
average SIt+1 are more likely to be overestimated, which is to be expected. The bimodal peak 
for the 2D model present in SIt is similarly present here. 
While the data set employed is heterogenous, spanning multiple ICUs and glycaemic control 
protocols across a number of years, it still represents a small portion of the full range of patient 
populations and clinical standards of care. As such, validation of the model across additional 
patient data sets drawn from different ICUs with different protocols would add further 
robustness to the validation of the 3D model. Another important limitation of this study is the 
lack of data on actual effects on clinical hyper- and hypo- glycaemic incidents from using the 
3D stochastic model for prediction, the ultimate end goal of any modifications to the STAR 




interaction should be assessed, or experimental/clinical work done to assess whether the 
benefits provided here translate into improved clinical performance. Virtual trials [39] would 
be a first major step in showing improved utility, and this will constitute future work exploring 
if the narrowing of SI prediction ranges translates to appreciatively tighter and safer glycaemic 
control. 
Overall, between the log transformation of the data and the addition of Gt as a data axis, the 3D 
model appears to better represent the probability field, provide more accurate predictions of 
SIt+1 and remove the causes for some undesirable behaviour in the 2D stochastic model. It is 
worth noting the 3D model does not require any data not currently gathered and used in the 
STAR protocol, and that, with the computational optimisations mentioned, the increase in 
computational load or runtime associated with adding this additional data axis is not significant 
on a clinical time scale. Thus, the improvements listed above can be provided for negligible 
computational or clinical cost and effort. While this study employs SPRINT and STAR data, 







A 3D stochastic model was developed for the prediction of future patient SI in the ICU. This 
model was compared to an existing, 2D stochastic model employed by the STAR controller 
over a retrospective cohort of 65,269 data points across 1,525 patients. The 3D stochastic model 
was shown to provide a better representation of the overall probability field, with a notably 
better conformation to expected percentage of data points within, above and below various 
credible interval widths while undergoing five-fold cross validation. The 3D stochastic model 
also provided more accurate predictions of SI, with an 18.12% narrower credible interval width 
on average, and a narrower credible interval width in 96.35% of cases. Finally, it was shown 
that the 2D stochastic model has a tendency to overestimate SI for patients with high blood 
glucose, and underestimate SI for patients with low blood glucose, increasing the risk of hyper- 
and hypo- glycaemia, respectively. In contrast, the 3D stochastic model was shown to 
completely avoid this tendency. As such, there is a clear case for further evaluation as to 
whether these improvements in predictive performance translate into an improvement in 
clinical hypo- and hyper- glycaemia rates when coupled with the STAR controller in an ICU. 
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Silverman’s rule of thumb is used to calculate a local kernel standard deviation, σloc, from a 
global standard deviation, σgbl. For k data point and n dimensions, Silverman’s rule of thumb 









𝑛+4 × 𝜎gbl 
(A1) 
Eq. A1 can be modified to give a kernel specific local standard deviation using a relative local 














× 𝜎gbl (A2) 
where ρloc is the kernel data point density, in ortho-normalised space, within a radius k-⅐ (for 
the 3D case) from a given kernel data point, and ρgbl is the global kernel data point density, 

























where m is the number of ortho-normalised kernel data points that lie within a radius k-⅐ from 
a given kernel data point, and RZ is defined as the radius from the global ortho-normalised 




Substituting Eq. A4 into Eq. A2 with n = 3 yields: 












And as, in ortho-normalised space, σ̃gbl is 1 in every direction, Eq. A5 can be further simplified: 

















Working in ortho-normalised space, for a given transformed 2D sample point ỹ1:2, the 
conditional 1D PDF is exists along a line, Ỹ, defined by varying ỹ3. This behaviour is consistent 
with the non-transformed  case where Y is defined by varying y3 due to the transformation 
matrix A being upper triangular i.e. only ỹ3 varies as y3 is varied. The goal is to define the 
region on the line Ỹ where the distance from a given kernel centre point, xj̃, to the sample point, 
ỹ, is less than 5 kernel standard deviations, σ̃j: 
‖?̃? − ?̃?𝑗‖2 < 5?̃?𝑗 (B1) 
The minimum possible distance between the line Ỹ and the kernel centre point xj̃ occurs when 
ỹ3 = xj,3, and the norm reduces to the norm of the first 2, fixed components of each: 
‖?̃?1:2 − ?̃?𝑗,1:2‖2 < 5?̃?𝑗 (B2) 
If the condition in B2 is not satisfied, the current kernel centre point has almost no effect on 
the PDF along the line Ỹ, and the method iterates immediately to the next kernel centre point. 
If the condition in B2 is satisfied, iteration now occurs across the set of points on Ỹ within a 
radius 5σ̃j from xj̃, defined by restricting the range of ỹ3: 
x̃𝑗,3 −√(5?̃?𝑗)
2
− (?̃?1:2 − ?̃?𝑗,1:2)
2
≥ ?̃?3 ≥ x̃𝑗,3 +√(5?̃?𝑗)
2
− (?̃?1:2 − ?̃?𝑗,1:2)
2
 (B3) 
and iterating between these minimum and maximum values for ỹ3, rather than across the full 
possible range of values, unless the existing minimum or maximum values are already more 
restrictive. Note that these bounds are specific to both the sample line, Ỹ, and kernel point, xj̃. 
 
